Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Accounts Payables (2020 - 2026)

MoonLake Immunotherapeutics' Accounts Payables history spans 7 years, with the latest figure at $23.4 million for Q1 2026.

  • Quarterly Accounts Payables rose 94.74% to $23.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $23.4 million through Mar 2026, up 94.74% year-over-year, with the annual reading at $29.6 million for FY2025, 228.66% up from the prior year.
  • Accounts Payables came in at $23.4 million for Q1 2026, down from $29.6 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $29.6 million in Q4 2025 to a low of $254972.0 in Q4 2022.
  • The 5-year median for Accounts Payables is $4.8 million (2023), against an average of $9.4 million.
  • Year-over-year, Accounts Payables crashed 83.75% in 2022 and then skyrocketed 620.74% in 2023.
  • MoonLake Immunotherapeutics' Accounts Payables stood at $254972.0 in 2022, then surged by 620.74% to $1.8 million in 2023, then skyrocketed by 389.31% to $9.0 million in 2024, then skyrocketed by 228.66% to $29.6 million in 2025, then fell by 20.89% to $23.4 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Accounts Payables are $23.4 million (Q1 2026), $29.6 million (Q4 2025), and $25.3 million (Q3 2025).